Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 15Breast Cancer Metastatic 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1HR Positive HER2 Negative Advanced Breast Cancer 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Non-Small-Cell Lung 1Breast Diseases 1Advanced Breast Cancer 1

Interventions

abemaciclib 3ribociclib 2palbociclib 2exemestane 2Tamoxifen 2Fulvestrant 2Anastrozole 2sacubitril and valsartan sodium hydrate drug combination 1elacestrant 1dalpiciclib 1STX-478 1RAD1901 1Metformin 1Letrozole 1Imlunestrant 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Breast Diseases × dalpiciclib × Clear all
NCT07581834 2026-05-12

Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study

Fujian Cancer Hospital

Phase 2 Recruiting
2,000 enrolled
Breast

Breast Diseases, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡